2011
DOI: 10.1016/j.lpm.2010.10.011
|View full text |Cite
|
Sign up to set email alerts
|

Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
13
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(17 citation statements)
references
References 20 publications
4
13
0
Order By: Relevance
“…Here we present a cohort of subjects with TIO in whom a 3‐day regimen of octreotide was prescribed in an attempt to reduce FGF23 levels. Consistent with most previous case‐reports on the same topic, octreotide was ineffective and did not modify FGF23 secretion or phosphate status in any subject.…”
Section: Discussionsupporting
confidence: 90%
See 2 more Smart Citations
“…Here we present a cohort of subjects with TIO in whom a 3‐day regimen of octreotide was prescribed in an attempt to reduce FGF23 levels. Consistent with most previous case‐reports on the same topic, octreotide was ineffective and did not modify FGF23 secretion or phosphate status in any subject.…”
Section: Discussionsupporting
confidence: 90%
“…One could argue that the lack of effects observed in our cohort compared to the patient reported by Seufert and colleagues could be secondary to shorter treatment duration (3 days in our cohort versus 13 days), but this is unlikely because biochemical improvement was evident during the first days in Seufert and colleagues’ case despite a lower initial octreotide dose than the one we employed. Additional reports have shown that octreotide therapy given for ≥2 months in two TIO patients was ineffective, with no observable changes in phosphate homeostasis . It is possible that the patient studied by Seufert and colleagues expressed an unusual array of SSTRs because mRNA analysis of the PMT showed expression for both SSTR2 and SSTR5, albeit much weaker for the latter.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…Basing on high Octreotide uptake in tumor, we decided to use the long acting analogue of Somatostatine, followed by short acting Octreotide in order to amplify the effect of medication on the phosphorus blood levels. We found similar cases in the literature; unfortunately most authors described that Sandostatin analogues allowed to decrease FGF-levels but failed to restore normal phosphorus level [1012]. In our patient phosphorus level after the Octreotide injection was also still low; however it increased from extremely low values to values near normal ranges with evident improvement of clinical outcomes.…”
Section: Discussionsupporting
confidence: 77%
“…As a result of the presence of somatostatin receptors on these tumors, it has been suggested that octreotide, a synthetic somatostatin analogue, would be useful in decreasing FGF-23 secretion [20]. Although there is one case report regarding use of octreotide as mitigating therapy before definitive treatment [20], few clinicians have been successful in repeating the initial success with this technique [3,4,13,16]. One of our patients underwent a trial of octreotide chemotherapy, but this was unsuccessful.…”
Section: Discussionmentioning
confidence: 98%